Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLACE: Regorafenib and Pembrolizumab vs TACE/TARE in Intermediate-stage HCC
NCT04777851Phase 3Terminated
- Sponsor
- Translational Research In Oncology
- Start
- Oct 2023
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of regorafenib, pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Translational Research In Oncology. Started Oct 2023; status: terminated.
02
Drugs
regorafenibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04777851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777851.